The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy

British Journal of Urology

Volumn 77, Issue 3, 1996, Pages 418-422

  Van Iersel, M P ^a   Thomas, C M G ^a   Segers, M F G ^a   Witjes, W P J ^a   Debruyne, F M J ^a   Oosterhof, G O N ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Prostate specific antigen; Prostatic carcinoma; Radical prostatectomy; Ultrasensitive assay

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0029971316     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1996.91017.x     Document Type: Article

References (26)

1. Oesterling JE, Chan DW, Epstein JL et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988; 139: 766-72
2. Lange PH, Ercole Cf. Lightner DJ, Fraley EE. Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J L/rol 1989: 141: 873-9
3. Schild SE. Wong WW, Grado GL et al. Radiotherapy for isolated increases prostate-specific antigen after radical prostatectomy. Mayo-Clin-Proc 1994; 69: 613-9
4. Goldrath DE. Messing EM. Prostate specific antigen: not detectable despite tumour progression after radical prostatectomy. J Urol 1989: 142: 1082-4
5. Takayama TK. Krieger JN. True LD. Lange PH. Recurrent prostate cancer despite undetectable prostate specific antigen. J Ural 1992; 148: 1541-2
6. Partin AW. Pound CR, Pearson JD et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant métastases. Urology 1994: 43: 649-59
7. Takayama TK. Vessella RL. Lange PH. A brief review of ultrasensitive prostate-specific antigen assays for the evaluation of patients after radical prostatectomy. World J Urol 1993: 11: 192-5
8. Stamey TA. Graves HCB. Wehner N. Ferrare M. Freiha FS. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993; 149: 787-92
9. Prestigiacomo AF, Stamey TA. A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol 1994; 152: 1515-9
10. Vesella RL, Lange PH. Issues in the assessment of PSA immunoassays. Urol Clin North Am 1993; 4: 607-19
11. Stamey TA. Yang N, Hay AR. McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl }Med 1987; 317: 909-16
12. van Straalen JP, Bossens MM, de Reijke TM, Sanders GT. Biological half-life of prostate-specific antigen after radical prostatectomy. Eur J Clin Chem Clin Biochem 1994; 32: 53-5
13. Graves HCB. Prostate-specific antigen comes of age in diagnosis and management of prostate cancer. Clin Chem 1992: 38: 1930-2
14. Elgamal AA, Van de Voorde W, Van Poppel H, Lauweryns J, Baert L. Immunohistochemical localization of prostatespecific markers within the accessory male sex glands of Cowper, Littre, and Morgagni. Urology 1994; 44: 84-90
15. Elgamal AA. Billen J, van de Voorde W et al. Extra prostatic sources of PSA, does it infer the subjective biochemical recurrence after radical prostatectomy? J Urol 1995: 153: 518A
16. Oesterling JE, Arbor A, Martin SK, Bergstralh EJ, Yemoto CEM, Stamey TA. The periurethral glands do not have a clinically significant effect on the serum PSA concentration. J Urol 1995; 153: 518A
17. Henttu P. Vihko P. cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Comm 1989: 160: 903-10
18. Klee GG, Preissner CM, Oesterling JE. Development of a highly sensitive immuno-chemiluminometric assay for prostate-specific antigen. Urology 1994; 44: 76-82
19. Sanders WH, Cooner WH. Woodward M, Graham SD. Detection of local recurrence after radical prostatectomy. J Urol 1995; 153: 518A
20. Kurth KH. de Reijke TM. de Haes H. Quality of life assessment in patients with prostatic carcinoma category Tl-3 Nl-3 MO. who received or did not receive hormonal treatment. J Urol 1995; 153:238A
21. Morgan WR, Bergstrahl EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage (T3) prostate cancer. Urology 1993; 41: 113-20
22. Zincke H. Oesterling JE. Blute ML. Bergstrahl EJ, Myers RP. Barett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (Stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-7
23. Walsh PC, Partin AW. Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831-6
24. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 1821-5
25. Ohori M. Goad JR. Wheeler TM, Eastham JA. Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-9
26. Catalona WJ. Smith DS. 5-year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-42